New Steroid-Sparing Drug Could Reduce Rheumatology Risks
A new trial shows promising results for a targeted compound that may minimize long-term systemic steroid exposure.
Updated on Oct. 20, 2026 in Arthritis
Live Poll
Would you prefer using targeted drug therapies to avoid the side effects of traditional steroids?
101 Therapeutics will present data on its investigational drug, 101-PGC-005, at the ACR Convergence 2026 meeting in Orlando on November 8, 2026. The clinical findings detail a Phase 2/3 trial evaluating the efficacy of the compound in patients with moderate COVID-19 compared to standard dexamethasone treatment.
Why it matters
Researchers are investigating 101-PGC-005 as a potential steroid-sparing therapy that could offer effective care while reducing systemic corticosteroid exposure. This approach aims to minimize the long-term side effects typically associated with traditional steroid regimens in rheumatology.
A Phase 2/3 trial involving 309 patients with moderate COVID-19 reported a hazard ratio of 2.31 for clinical improvement and 1.47 for viral clearance when using 101-PGC-005 compared to systemic dexamethasone. The study results are preliminary and currently awaiting formal presentation.
The players
101 Therapeutics
A pharmaceutical developer researching steroid-sparing adjuncts for use in rheumatology indications.
The details
The drug 101-PGC-005 functions as a CD206-targeted dexamethasone prodrug, which is designed to deliver glucocorticoids specifically to macrophages. By targeting these immune cells, the treatment aims to provide therapeutic benefits while maintaining a cumulative exogenous corticosteroid exposure of 0 mg. This mechanism differentiates it from traditional systemic dexamethasone, which is administered more broadly.
Timeline
November 6-11, 2026, marks the dates for the ACR Convergence 2026 meeting.
The clinical data is scheduled for poster presentation on November 8, 2026.
Health Landscape
The clinical investigation of 101-PGC-005 aligns with a broader push in rheumatology to develop targeted therapies that avoid systemic steroid side effects. This approach marks a potential evolution in managing inflammatory diseases through more precise, receptor-based delivery systems.
Patients with rheumatologic conditions may want to discuss new research on steroid-sparing therapies with their physician to understand future treatment possibilities. As this drug is currently in the trial phase, it is not yet an available option for patient care.
The takeaway
Targeted therapies like 101-PGC-005 are being studied to offer the benefits of steroids without the systemic exposure that can lead to long-term health complications. Patients should monitor future clinical developments in rheumatology and consult their doctor about emerging treatment options.
Further reading
Learn more about evolving treatment standards for Arthritis.
Live Poll
Would you prefer using targeted drug therapies to avoid the side effects of traditional steroids?
